The interview aims to examine the FDA approval of Itvisma (onasemnogene abeparvovec-brve), the first and only gene replacement therapy approved for children two years and older, adolescents, and adults with spinal muscular atrophy (SMA). The discussion will focus on the Phase III STEER and STRENGTH clinical trial results, the clinical impact of one-time SMN1 gene replacement, long-term motor function stabilization, safety outcomes, and the implications of expanding gene therapy access across all age groups living with SMA.